Onesource Specialty Pharma logo

Onesource Specialty Pharma MD, chairman, board of directors and AGM

NSE: ONESOURCEBSE: 544292Pharmaceuticals & BiotechnologySmall Cap

Last close ₹1,334.10down ₹43.70 (3.17%)BSE ₹1,332.70

Share price at the NSE close on 23 Oct 2026. Previous close ₹1,377.80.

52-week range of traded prices to 23 Oct 2026
₹1,057.00Low, 30 Jan 2026₹1,925.00High, 3 Nov 2025
Market cap
₹15,299 Cr373rd largest listed
P/E
Lossover the last 12 months
P/B
2.6
Dividend yield
Nonein the last 12 months
ROE
−0.8%
ROE without one-offs
−0.6%
ROCE
0.8%
Debt to equity
0.22
Volume, NSE
2,06,52963.5% delivered

Onesource Specialty Pharma board of directors

At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.Their trades in its shares

  • ChairpersonArun Kumar PillaiRelated to the promoter
  • Managing directorNeeraj Sharma
  • Company Secretary and Compliance OfficerTrisha Allada

8 directors5 independent1 executive2 non-executive

  • Arun Kumar Pillai · ChairpersonNon-executive · joined Apr 2021 · 3 listed boards · 1 committee seat
  • Neeraj Sharma · Managing directorExecutive · joined Mar 2024 · 1 listed board · 2 committee seats
  • Debarati SenIndependent · joined Feb 2025 · reappointed Feb 2025 · 16 months as independent · 1 listed board · 1 as independent · 1 committee seat
  • Claudio AlbrechtIndependent · joined Feb 2025 · reappointed Feb 2025 · 16 months as independent · 2 listed boards · 2 as independent
  • Vijay Paul KarwalIndependent · joined Feb 2025 · reappointed Feb 2025 · 16 months as independent · 1 listed board · 1 as independent · 1 committee seat
  • Bharat Dhirajlal ShahNon-executive · joined Jul 2024 · 1 listed board · 2 committee seats, 1 as chair
  • Rashmi Harshadrai BarbhaiyaIndependent · joined May 2024 · reappointed May 2024 · 25 months as independent · 1 listed board · 1 as independent · 1 committee seat
  • Colin Michael BondIndependent · joined Jun 2025 · reappointed Jun 2025 · 12 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair

An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.

4 directors who left
  • Bhushan Sudhir Bopardikar, left 27 Feb 2025: Others
  • Mahadevan Narayanamoni, left 27 Feb 2025: Others
  • Gopakumar Gopalan Nair, left 27 Feb 2025: Others
  • Rajashri Santosh Kumar Ojha, left 27 Feb 2025: Others

Committees and meetings

Who sits on each, and how often they met.Board meeting notices and outcomes

  • Board

    • 13 May 20267 of 8 present4 independent · 67 days in between
    • 6 Mar 20267 of 8 present5 independent · 41 days in between
    • 23 Jan 20268 of 8 present5 independent

  • Audit Committee

    Chair Colin Michael Bond

    Debarati Sen, Vijay Paul Karwal, Neeraj Sharma

    • 12 May 20264 of 4 present3 independent · 101 days in between
    • 30 Jan 20263 of 4 present3 independent · 6 days in between
    • 23 Jan 20264 of 4 present3 independent

  • Nomination and remuneration committee

    Chair Vijay Paul Karwal

    Debarati Sen, Claudio Albrecht, Bharat Dhirajlal Shah

    • 13 May 20264 of 4 present3 independent · 109 days in between
    • 23 Jan 20264 of 4 present3 independent

  • Stakeholders Relationship Committee

    Chair Bharat Dhirajlal Shah

    Neeraj Sharma, Rashmi Harshadrai Barbhaiya

    • 12 May 20263 of 3 present1 independent · 108 days in between
    • 23 Jan 20263 of 3 present1 independent

  • Risk Management Committee

    Chair Vijay Paul Karwal

    Neeraj Sharma, Debarati Sen

    • 12 May 20263 of 3 present2 independent · 108 days in between
    • 23 Jan 20263 of 3 present2 independent

  • Corporate Social Responsibility Committee

    Chair Debarati Sen

    Vijay Paul Karwal, Bharat Dhirajlal Shah, Neeraj Sharma

    • 12 May 20264 of 4 present2 independent · 108 days in between
    • 23 Jan 20264 of 4 present2 independent

Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.

Statutory auditor

Named in the results for the quarter to Jun 2026.

  • Deloitte Haskins & SellsPeer-review certificate valid to Apr 2028

A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.

Onesource Specialty Pharma AGM and shareholder votes

Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Onesource Specialty Pharma share news and announcements

Annual general meeting, 23 Sep 2026

81,594 shareholders on the register on 16 Sep 2026; present: 16 promoters and 65 others; votes counted by NIDHI SHREE J / V SREEDHARAN AND ASSOCIATES.The company's voting result (opens in a new tab)

  1. Adoption of Financial Statements
    Ordinary
    99.75% for0.25% against

    Against: promoters 0.00% · institutions 0.49% · other public 0.00%

    Turnout: all 78.84% · promoters 99.92% · institutions 91.91% · other public 31.89%

  2. Re-appointment of Neeraj Sharma (DIN: 09402652), retiring Director
    Ordinary
    97.05% for2.95% against

    Against: promoters 0.00% · institutions 5.80% · other public 0.00%

    Turnout: all 78.79% · promoters 99.92% · institutions 91.91% · other public 31.70%

  3. Appointment and Fixation of Remuneration of Statutory Auditors
    Ordinary
    96.23% for3.77% against

    Against: promoters 0.00% · institutions 7.41% · other public 0.00%

    Turnout: all 78.84% · promoters 99.92% · institutions 91.91% · other public 31.89%

  4. Additional Remuneration payable to Neeraj Sharma (DIN: 09402652), Managing Director for financial year ended March 31, 2026
    Special
    94.46% for5.54% against

    Against: promoters 0.00% · institutions 10.87% · other public 0.04%

    Turnout: all 78.79% · promoters 99.92% · institutions 91.91% · other public 31.70%

  5. Commission payable to Non-Executive Independent Directors of the Company
    Special
    98.40% for1.60% against

    Against: promoters 0.00% · institutions 3.13% · other public 0.04%

    Turnout: all 78.84% · promoters 99.92% · institutions 91.91% · other public 31.89%

  6. Approval of material related party transactions (RPTs) of the Company with Strides Pharma Science Limited
    OrdinaryPromoters have an interest in it
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.04%

    Turnout: all 47.42% · promoters 0.00% · institutions 91.91% · other public 28.12%

  7. Approval of material related party transactions (RPTs) of the Company with Strides Pharma Inc, USA, (Wholly owned subsidiary (WOS) of Strides Pharma Science Limited)
    OrdinaryPromoters have an interest in it
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.04%

    Turnout: all 47.42% · promoters 0.00% · institutions 91.91% · other public 28.12%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 22 Sep 2025, 6 resolutions

91,044 shareholders on the register on 15 Sep 2025; present: 4 promoters and 45 others; votes counted by Pradeep B Kulkarni / V Sreedharan & Associates.The company's voting result (opens in a new tab)

  1. To consider and adopt (a) the audited standalone financial statement of the Company for the financial year ended March 31, 2025 and the reports of the Board of Directors and Auditors thereon; and (b) the audited consolidated financial statement of the Company for the financial year ended March 31, 2025 and the report of Auditors thereon.MoreLess
    Ordinary
    99.88% for0.12% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.33%

    Turnout: all 62.96% · promoters 84.34% · institutions 74.86% · other public 46.23%

  2. Re-appointment of Arun Kumar (DIN: 00084845), retiring Director
    Ordinary
    95.91% for4.09% against

    Against: promoters 0.00% · institutions 0.00% · other public 10.81%

    Turnout: all 62.98% · promoters 84.34% · institutions 74.86% · other public 46.28%

  3. Remuneration payable to M. Ashok Kumar, CostAuditor of the Company for FY 2025-26
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 62.98% · promoters 84.34% · institutions 74.86% · other public 46.26%

  4. Appointment of M/s. DV & Associates, Company Secretaries (Firm Registration No. P2020KE83600) as the Secretarial Auditors of the Company for a term of 5 (five) consecutive years
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 62.98% · promoters 84.34% · institutions 74.86% · other public 46.28%

  5. Approval of material related party transactions (RPTs) of the Company with Strides Pharma Science Limited
    OrdinaryPromoters have an interest in it
    92.27% for7.73% against

    Against: promoters 0.00% · institutions 20.75% · other public 0.00%

    Turnout: all 37.78% · promoters 0.00% · institutions 74.86% · other public 46.10%

  6. Approval of material related party transactions (RPTs) of the Company with Strides Pharma Inc, USA, (Wholly owned subsidiary (WOS) of Strides Pharma Science Limited)
    OrdinaryPromoters have an interest in it
    92.27% for7.73% against

    Against: promoters 0.00% · institutions 20.75% · other public 0.00%

    Turnout: all 37.78% · promoters 0.00% · institutions 74.86% · other public 46.10%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 30 Jul 2025, 2 resolutions

90,407 shareholders on the register on 27 Jun 2025; votes counted by PRADEEP B KULKARNI / V SREEDHARAN AND ASSOCIATES.The company's voting result (opens in a new tab)

  1. Appointment of Mr. Colin Michael Bond (DIN: 10982819) as an Independent Director of the Company for a term of five years, not liable to retire by rotation.
    Special
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 0.10% · other public 0.01%

    Turnout: all 63.91% · promoters 89.73% · institutions 83.81% · other public 23.61%

  2. Revision in remuneration of Mr. Neeraj Sharma (DIN: 09402652), Managing Director (“MD”) of the Company.
    Special
    82.93% for17.07% against

    Against: promoters 0.00% · institutions 38.02% · other public 0.02%

    Turnout: all 63.90% · promoters 89.73% · institutions 83.78% · other public 23.61%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 25 May 2025, 3 resolutions

84,995 shareholders on the register on 18 Apr 2025; votes counted by PRADEEP B KULKARNI / V SREEDHARAN AND ASSOCIATES.The company's voting result (opens in a new tab)

  1. Appointment of Ms. Debarati Sen (DIN:07521172) as an Independent Director of the Company for a term of five years, not liable to retire by rotation
    Special
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 74.50% · promoters 100.00% · institutions 88.84% · other public 33.65%

  2. Appointment of Dr. Claudio Albrecht (DIN:10109819) as an Independent Director of the Company for a term of five years, not liable to retire by rotation
    Special
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 74.49% · promoters 100.00% · institutions 88.82% · other public 33.65%

  3. Appointment of Mr. Vijay Paul Karwal (DIN: 10905781) as an Independent Director of the Company for a term of five years, not liable to retire by rotation
    Special
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 74.50% · promoters 100.00% · institutions 88.84% · other public 33.65%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

How mutual funds voted

Fund houses must disclose how they vote at every meeting of a company they hold.Funds that hold it

Mutual fund votes, meeting of 23 Sep 2026, 10 fund houses so far (houses' deadline to file 15 Oct 2026)

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

  • Adoption of Financial Statements
    10 for0 against
  • Re-appointment of Neeraj Sharma (DIN: 09402652), retiring Director
    10 for0 against
  • Appointment and Fixation of Remuneration of Statutory Auditors
    3 for0 against
  • Additional Remuneration payable to Neeraj Sharma (DIN: 09402652), Managing Director for financial year ended March 31, 2026
    10 for0 against
  • Commission payable to Non-Executive Independent Directors of the Company
    Against DSP Mutual Fund, Jio BlackRock Mutual Fund
    • DSP Mutual Fund, Jio BlackRock Mutual FundThe aggregate remuneration — commission and sitting fees — payable to each Independent Director is proposed to be capped at Euro 80,000 (~Rs. 8.8 mn) per annum, for three years from FY26. Commission payable to each Independent Director shall be arrived at after adjusting the sitting fees paid during the year. Independent Directors received no commission in FY25 and FY26; sitting fees aggregated Rs. 7.3 mn and Rs. 6.4 mn respectively. We recognize that the board comprises Independent Directors well established in their respective fields, and that payment of commission is standard market practice. However, considering the size and scale of the business and company yet to turn profitable, the proposed remuneration cap per director of ~Rs. 8.8 mn – resulting in an aggregate outflow of about Rs. 44.0 mn across five Independent Directors, is high. We note that the company has provided a benchmark wherein the proposed remuneration is comparable against listed pharmaceutical companies – based on market capitalization, however financial performance of the company should also be a benchmark for payment of commission. We do not support the resolution.
    8 for2 against
  • Approval of material related party transactions (RPTs) of the Company with Strides Pharma Science Limited
    10 for0 against
  • Approval of material related party transactions (RPTs) of the Company with Strides Pharma Inc, USA, (Wholly owned subsidiary (WOS) of Strides Pharma Science Limited)
    10 for0 against
1 proposal not matched to one resolution
  • Appointment of M/s. B S R and Co LLP, Chartered Accountants (Firm Registration No.: 101248W/W-100022), as the Statutory Auditors of the Company, to hold office for a period of 5 (five) consecutive years from the conclusion of the 19th Annual General Meeting until the conclusion of the 24th Annual General Meeting of the Company, at such remuneration as may be mutually agreed upon between the Board of Directors of the Company and the Statutory Auditors.MoreLess
    Against Angel One Mutual Fund, Edelweiss Mutual Fund, ICICI Prudential Mutual Fund, LIC Mutual Fund, Navi Mutual Fund
    • Angel One Mutual FundGovernance Concern: OneSource (the Company) became a ‘specialty pharmaceutical CDMO’ as a result of merger of Identified CDMO Business and Soft Gelatin Business of Strides Pharma Science Limited (Strides) in 2024 and the proposed auditors have been associated with Strides since 2017; hence, the proposed auditors have been associated with the material business undertaking of the Company since 2017. And, further the proposed appointment until the 24th AGM (to be held in 2031) will lead to prolonged association of the auditors with the Company’s material business undertaking, which was demerged from Strides to the Company.
    • Edelweiss Mutual Fund, Navi Mutual FundCompliant with law. No concern identified on the merits of the proposed Statutory Auditors. Governance Concern: OneSource (the Company) became a ‘specialty pharmaceutical CDMO’ as a result of merger of Identified CDMO Business and Soft Gelatin Business of Strides Pharma Science Limited (Strides) in 2024 and the proposed auditors have been associated with Strides since 2017; hence, the proposed auditors have been associated with the material business undertaking of the Company since 2017. And, further the proposed appointment until the 24th AGM (to be held in 2031) will lead to prolonged association of the auditors with the Company’s material business undertaking, which was demerged from Strides to the Company.
    • ICICI Prudential Mutual FundProlonged association of the auditors with the Company’s material business undertaking. Hence, the AMC has voted against the resolution.
    • LIC Mutual FundCompliant with law. No concern identified on the merits of the proposed Statutory Auditors. Governance Concern: OneSource (the Company) became a specialty pharmaceutical CDMO as a result of merger of Identified CDMO Business and Soft Gelatin Business of Strides Pharma Science Limited (Strides) in 2024 and the proposed auditors have been associated with Strides since 2017; hence, the proposed auditors have been associated with the material business undertaking of the Company since 2017. And, further the proposed appointment until the 24th AGM (to be held in 2031) will lead to prolonged association of the auditors with the Company s material business undertaking, which was demerged from Strides to the Company.
    2 for5 against

Mutual fund votes, meeting of 22 Sep 2025, 11 fund houses

  • To consider and adopt (a) the audited standalone financial statement of the Company for the financial year ended March 31, 2025 and the reports of the Board of Directors and Auditors thereon; and (b) the audited consolidated financial statement of the Company for the financial year ended March 31, 2025 and the report of Auditors thereon.MoreLess
    11 for0 against
  • Re-appointment of Arun Kumar (DIN: 00084845), retiring Director
    11 for0 against
  • Remuneration payable to M. Ashok Kumar, CostAuditor of the Company for FY 2025-26
    11 for0 against
  • Appointment of M/s. DV & Associates, Company Secretaries (Firm Registration No. P2020KE83600) as the Secretarial Auditors of the Company for a term of 5 (five) consecutive years
    11 for0 against
  • Approval of material related party transactions (RPTs) of the Company with Strides Pharma Science Limited
    11 for0 against
  • Approval of material related party transactions (RPTs) of the Company with Strides Pharma Inc, USA, (Wholly owned subsidiary (WOS) of Strides Pharma Science Limited)
    11 for0 against
2 earlier meetings

Mutual fund votes, meeting of 30 Jul 2025, 10 fund houses

  • Appointment of Mr. Colin Michael Bond (DIN: 10982819) as an Independent Director of the Company for a term of five years, not liable to retire by rotation.
    10 for0 against
  • Revision in remuneration of Mr. Neeraj Sharma (DIN: 09402652), Managing Director (“MD”) of the Company.
    Against LIC Mutual Fund, Motilal Oswal Mutual Fund
    • LIC Mutual FundConcerns over - Proposal for revision in remuneration not supported with mandatory details such as attendance at Board Meetings held during the year. Governance & Transparency Concern: No major concern on the proposed quantum of remuneration per-se; however, no absolute cap on the potential ESOP benefits. Further, the proposal also seeks approval for remuneration payment in case of loss/inadequacy of profits, however, there is no explicit mention that such an approval is valid for not more than 3 years and that separate approval will be sought in case loss/inadequacy situation prevails beyond 3 years.
    • Motilal Oswal Mutual FundNon-Compliant with Secretarial Standards – 2: Proposal for revision in remuneration not supported with mandatory details such as attendance at Board Meetings held during the year. Governance & Transparency Concern: No major concern on the proposed quantum of remuneration per-se; however, no absolute cap on the potential ESOP benefits. Further, the proposal also seeks approval for remuneration payment in case of loss/inadequacy of profits, however, there is no explicit mention that such an approval is valid for not more than 3 years and that separate approval will be sought in case loss/inadequacy situation prevails beyond 3 years.
    8 for2 against

Mutual fund votes, meeting of 25 May 2025, 9 fund houses

  • Appointment of Ms. Debarati Sen (DIN:07521172) as an Independent Director of the Company for a term of five years, not liable to retire by rotation
    9 for0 against
  • Appointment of Dr. Claudio Albrecht (DIN:10109819) as an Independent Director of the Company for a term of five years, not liable to retire by rotation
    9 for0 against
  • Appointment of Mr. Vijay Paul Karwal (DIN: 10905781) as an Independent Director of the Company for a term of five years, not liable to retire by rotation
    9 for0 against

Each fund house counted once, from its own disclosure; the reasons are its own words.

Investor complaints and compliance

Quarter by quarter.

Investor complaints received and resolved, the company's own count

  • Received
  • Resolved

Open at the quarter's end

None open at any quarter's end.
The board is made up as the listing rules require
Yes
The board has a regular chairperson
Yes
The company has a risk management committee
Yes
The chair is related to the managing director
No
The filing has a part on fines and penalties
No
The filing has a part on tax disputes
No
There was a cyber security incident in the quarter
No

The company's own answers in its filing.

How money raised was used

The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it.